Camurus announces approval of Oczyesa (octreotide SC) for the treatment of acromegaly in the UK

Camurus  announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Oczyesa, (octreotide subcutaneous depot), marketing authorization for the maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogs.

”Oczyesa, the first once-monthly subcutaneous octreotide treatment, has shown effective and sustained control of acromegaly and can be self-administered by patients using an autoinjector pen”, says Fredrik Tiberg, President & CEO, CSO at Camurus. ”Camurus plans to launch the treatment in the UK in the fourth quarter of 2025.”

The MHRA’s marketing authorization of Oczyesa is based on the results from a comprehensive clinical program comprising seven clinical studies, including two Phase III studies within the ACROINNOVA program.

Oczyesa is formulated using Camurus’ proprietary FluidCrystal technology. The product is designed for convenient once-monthly, subcutaneous self-administration using a pre-filled autoinjector pen with a hidden, thin needle.